Search

Rhythm Pharmaceuticals Inc

Suletud

SektorTervishoid

90.18 -0.38

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

89.84

Max

90.89

Põhinäitajad

By Trading Economics

Sissetulek

-49M

-105M

Müük

11M

71M

Aktsiakasum

-0.73

Kasumimarginaal

-147.27

Töötajad

414

EBITDA

6.2M

-44M

Soovitused

By TipRanks

Soovitused

Tugev "osta" hinnang

12 kuu keskmine prognoos

+57.92% upside

Dividendid

By Acuity

Järgmine tulemuste avaldamine

3. nov 2026

Turustatistika

By TradingEconomics

Turukapital

-709M

6.3B

Eelmine avamishind

90.56

Eelmine sulgemishind

90.18

Rhythm Pharmaceuticals Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

9. okt 2026, 20:07 UTC

Social Media

Rhythm Pharmaceuticals shares advanced after BofA set a new price target of $150, supported by positive feedback on its MC4R franchise for adult hypothalamic obesity.

8. okt 2026, 20:01 UTC

News

RBC Capital raises Rhythm Pharmaceuticals price target to $159.00 from $155.00 while maintaining an Outperform rating, citing strong market performance over five years.

7. okt 2026, 19:25 UTC

Rhythm Pharmaceuticals Inc shares fell sharply, remaining well below their 20-day moving average and significantly lower compared to Tuesday's close.

6. okt 2026, 20:30 UTC

Rhythm Pharmaceuticals Inc is experiencing a significant decline in after-market trading, moving further below its 20-day moving average since Tuesday's close.

5. okt 2026, 20:30 UTC

Rhythm Pharmaceuticals Inc is trading lower in after-market hours, continuing a trend of six consecutive daily declines and remaining below its 20-day moving average.

2. okt 2026, 20:07 UTC

Rhythm Pharmaceuticals Inc shares fell sharply, continuing a downward trend with four consecutive sessions in the red and remaining below the 20-day moving average.

1. okt 2026, 20:13 UTC

Rhythm Pharmaceuticals Inc is advancing in after-market trading, gaining ground since Thursday's close while currently trading below its 20-day moving average.

29. sept 2026, 20:07 UTC

Rhythm Pharmaceuticals Inc shares fell sharply, declining notably from Monday's close and trading well below its 20-day moving average amid ongoing pressure.

24. sept 2026, 19:25 UTC

Rhythm Pharmaceuticals Inc shares fell modestly, currently near the lower end of their one-month range and below the 20-day moving average amid broader market weakness.

23. sept 2026, 22:25 UTC

Rhythm Pharmaceuticals Inc is rising in after-market trading, recovering from an initial dip and advancing since Wednesday's close, though still below its 20-day moving average.

22. sept 2026, 20:07 UTC

Event
Correlated Moves
News

Rhythm Pharmaceuticals' IMCIVREE® received Health Canada approval for weight management in patients with acquired hypothalamic obesity, boosting shares higher during the session.

21. sept 2026, 20:06 UTC

Rhythm Pharmaceuticals Inc is higher today, continuing an upward trend since Friday, despite mid-morning volatility and remaining below its 20-day moving average.

18. sept 2026, 20:06 UTC

Rhythm Pharmaceuticals Inc shares fell sharply, settling near the lower end of their one-month range and significantly below the 20-day moving average.

17. sept 2026, 20:07 UTC

Correlated Moves

Rhythm Pharmaceuticals advances during Thursday's session, boosted by a rally in the biotechnology sector following positive Phase 3 results for Moderna's cancer vaccine.

16. sept 2026, 20:10 UTC

Rhythm Pharmaceuticals Inc is experiencing an upward movement during Wednesday's trading session, recovering from an early low with a peak return of 4.17%.

15. sept 2026, 20:01 UTC

News

Rhythm Pharmaceuticals shares are lower amid concerns from CEO insider selling and a drop in the NY Empire State Manufacturing Index for September.

14. sept 2026, 20:08 UTC

Rhythm Pharmaceuticals Inc. shares are lower today, continuing a decline since Friday's close, despite an earlier rebound from session lows.

11. sept 2026, 19:52 UTC

Rhythm Pharmaceuticals shares are higher during Friday's session, pulling back from earlier gains. No specific news was identified to explain the movement.

8. sept 2026, 20:08 UTC

Correlated Moves

RYTM trades lower as the biotech sector faces pressure.

2. sept 2026, 20:08 UTC

News

Rhythm Pharmaceuticals is higher today, supported by gains in the Biotechnology sector and CFO share transactions that reflect confidence in future performance.

1. sept 2026, 19:26 UTC

News

Rhythm Pharmaceuticals reported a net loss of -$33.26 million on revenue of $17.28 million. Shares are lower, continuing a trend of three consecutive sessions finishing down.

31. aug 2026, 23:46 UTC

Rhythm Pharmaceuticals Inc shares rose in after-market trading, reflecting a gradual increase from earlier lows, though still below the 20-day moving average.

28. aug 2026, 20:02 UTC

News

Rhythm Pharmaceuticals Inc shares are lower as Deutsche Bank initiates coverage with a Hold rating and a price target of $120.

26. aug 2026, 20:08 UTC

News

Rhythm Pharmaceuticals is trading lower, influenced by declines in the Biotechnology sector and a broader market downturn since Tuesday's close.

25. aug 2026, 21:02 UTC

Rhythm Pharmaceuticals Inc shares are lower in after-market hours. No specific news was identified to explain the decline, contrasting recent upward trends.

21. aug 2026, 19:36 UTC

Rhythm Pharmaceuticals Inc shares are higher during Friday's session, reflecting positive market response. The stock reached a session high earlier before pulling back.

20. aug 2026, 20:02 UTC

Correlated Moves

Rhythm Pharmaceuticals is lower today, influenced by a significant decline in the Biotechnology sector and high trading volume. The stock has dropped sharply since Wednesday.

13. aug 2026, 19:51 UTC

Rhythm Pharmaceuticals is advancing amid broader market gains, supported by strong technology sector performance and high trading volume, despite no specific company news.

12. aug 2026, 19:46 UTC

Event

Rhythm Pharmaceuticals received expanded marketing authorization for IMCIVREE in the UK. Shares are trading higher since Tuesday's close, near the upper end of their one-month range.

11. aug 2026, 19:36 UTC

Social Media
News
Event

Rhythm Pharmaceuticals received expanded UK approval for IMCIVREE to treat obesity, yet shares are declining amid broader market sentiment concerns.

Võrdlus sarnastega

Hinnamuutus

Rhythm Pharmaceuticals Inc Prognoos

Hinnasiht

By TipRanks

57.92% tõus

12 kuu keskmine prognoos

Keskmine 143.364 USD  57.92%

Kõrge 160 USD

Madal 120 USD

Põhineb 14 Wall Streeti analüütiku instrumendi Rhythm Pharmaceuticals Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Tugev "osta" hinnang

14 ratings

13

Osta

1

Hoia

0

Müü

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

$

Ettevõttest Rhythm Pharmaceuticals Inc

Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome. It is in Phase 3 clinical trials for treating POMC or LEPR heterozygous deficiency obesities, steroid receptor coactivator 1 deficiency obesity, SH2B1 deficiency obesity, MC4 receptor deficiency obesity, and other MC4R disorders. The company has licensing agreements with LG Chem, Ltd; Ipsen Pharma S.A.S; Camurus; RareStone Group Ltd.; joint research collaboration with Axovia Therapeutics for developing in bardet-biedl syndrome; and LG Chem, Ltd. The company was formerly known as Rhythm Metabolic, Inc. and changed its name to Rhythm Pharmaceuticals, Inc. in October 2015. Rhythm Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.